Evidence mapPaperPMID 39430242Full record

ArticleInternational journal of biological sciences2024

KIF15 promotes human glioblastoma progression under the synergistic transactivation of REST and P300.

Wendan Yu, Shilong Han, Sheng Hu, Liyuan Ru, Chunyu Hua, Guoqing Xue, Guohui Zhang, Kuan Lv, Hanxiao Ge, Meiyi Wang and 6 more

Abstract read
In one paragraph

Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wendan YuInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Shilong HanInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Sheng HuInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Liyuan RuInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Chunyu HuaInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Guoqing XueInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Guohui ZhangInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Kuan LvInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Hanxiao GeInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Meiyi WangInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Lina ZhengInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Jie ZhouInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Shuai HouInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Yun TengInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
Wuguo DengSun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China.
Wei GuoInstitute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is highly invasive and lethal. The failure to cure GBM highlights the necessity of developing more effective targeted therapeutic strategies. KIF15 is a motor protein to be involved in cell mitosis promotion, cell structure assembly and cell signal transduction. The precise biological function and the potential upstream regulatory mechanisms of KIF15 in GBM remain elusive. Here, we demonstrated that KIF15 was abnormally up-regulated in GBM and predicted poor prognosis of GBM patients. KIF15 promotes GBM cell proliferation, metastasis and cell cycle progression. REST could bind to KIF15 promoter and transactivate KIF15. Furthermore, REST interacts with P300 and depends on its histone acetyltransferase (HAT) activity to co-regulate KIF15 expression. Both REST and P300 were highly expressed in GBM and predicted poor prognosis of GBM patients alone or in combination with KIF15. The tumorigenic function of KIF15 in GBM was regulated by REST

Indexed as

GlioblastomaKinesinsAnimalsCell Line, TumorCell ProliferationE1A-Associated p300 ProteinFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeRE1-Silencing Transcription FactorRepressor ProteinsTranscriptional ActivationE1A-Associated p300 ProteinEP300 protein, humanKIF15 protein, humanKinesinsRE1-Silencing Transcription FactorRepressor ProteinsAcetylationGlioblastoma (GBM)KIF15P300REST

Identifiers

PMID39430242
PMCPMC11488581

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.